High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results

M. Bruzzone; P. F. Conte; S. Chiara; F. Carnino; G. Giaccone; A. Conio; G. Bentivoglio; G. Pescetto; R. Rosso

High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results

M. Bruzzone, P. F. Conte, S. Chiara, F. Carnino, G. Giaccone, A. Conio, G. Bentivoglio, G. Pescetto, R. Rosso

Research output: Contribution to journal › Article › peer-review

Abstract

A substantial percentage of patients with advanced ovarian cancer will progress or relapse after platinum-based front therapies and will require salvage chemotherapy. In order to evaluate feasibility and effectiveness of high dose platinum (HD-CDDP) nine patients with ovarian cancer were treated with HD-CDDP while progressing after conventional doses of the same drug. Cisplatin 40 mg/M² d. 1 → 5 q. 28 days, was administered with forced chloruresis for a total of fifteen cycles. Preliminary results show a promising 44.4% response rate with acceptable toxicity: only one patient had to discontinue treatment because of severe combined toxicity including infection, mucositis, shaking tremors, ototoxicity and palmar hyperkeratosis.

Original language	English
Pages (from-to)	139-142
Number of pages	4
Journal	Chemioterapia
Volume	4
Issue number	2
Publication status	Published - 1985

ASJC Scopus subject areas

Pharmacology (medical)
Microbiology (medical)

Cite this

@article{dc4e1890d4ea4a8f930cd80f4fae65d6,

title = "High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results",

abstract = "A substantial percentage of patients with advanced ovarian cancer will progress or relapse after platinum-based front therapies and will require salvage chemotherapy. In order to evaluate feasibility and effectiveness of high dose platinum (HD-CDDP) nine patients with ovarian cancer were treated with HD-CDDP while progressing after conventional doses of the same drug. Cisplatin 40 mg/M2 d. 1 → 5 q. 28 days, was administered with forced chloruresis for a total of fifteen cycles. Preliminary results show a promising 44.4% response rate with acceptable toxicity: only one patient had to discontinue treatment because of severe combined toxicity including infection, mucositis, shaking tremors, ototoxicity and palmar hyperkeratosis.",

author = "M. Bruzzone and Conte, {P. F.} and S. Chiara and F. Carnino and G. Giaccone and A. Conio and G. Bentivoglio and G. Pescetto and R. Rosso",

year = "1985",

language = "English",

volume = "4",

pages = "139--142",

journal = "Chemioterapia",

issn = "0392-906X",

publisher = "Editrice Giuntina",

number = "2",

}

TY - JOUR

T1 - High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results

AU - Bruzzone, M.

AU - Conte, P. F.

AU - Chiara, S.

AU - Carnino, F.

AU - Giaccone, G.

AU - Conio, A.

AU - Bentivoglio, G.

AU - Pescetto, G.

AU - Rosso, R.

PY - 1985

Y1 - 1985

N2 - A substantial percentage of patients with advanced ovarian cancer will progress or relapse after platinum-based front therapies and will require salvage chemotherapy. In order to evaluate feasibility and effectiveness of high dose platinum (HD-CDDP) nine patients with ovarian cancer were treated with HD-CDDP while progressing after conventional doses of the same drug. Cisplatin 40 mg/M2 d. 1 → 5 q. 28 days, was administered with forced chloruresis for a total of fifteen cycles. Preliminary results show a promising 44.4% response rate with acceptable toxicity: only one patient had to discontinue treatment because of severe combined toxicity including infection, mucositis, shaking tremors, ototoxicity and palmar hyperkeratosis.

AB - A substantial percentage of patients with advanced ovarian cancer will progress or relapse after platinum-based front therapies and will require salvage chemotherapy. In order to evaluate feasibility and effectiveness of high dose platinum (HD-CDDP) nine patients with ovarian cancer were treated with HD-CDDP while progressing after conventional doses of the same drug. Cisplatin 40 mg/M2 d. 1 → 5 q. 28 days, was administered with forced chloruresis for a total of fifteen cycles. Preliminary results show a promising 44.4% response rate with acceptable toxicity: only one patient had to discontinue treatment because of severe combined toxicity including infection, mucositis, shaking tremors, ototoxicity and palmar hyperkeratosis.

UR - http://www.scopus.com/inward/record.url?scp=0022415357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022415357&partnerID=8YFLogxK

M3 - Article

C2 - 3891114

AN - SCOPUS:0022415357

VL - 4

SP - 139

EP - 142

JO - Chemioterapia

JF - Chemioterapia

SN - 0392-906X

IS - 2

ER -

High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this